Day One Biopharmaceuticals, Inc.
Key Highlights
- Day One Biopharmaceuticals acquired by Servier Pharmaceuticals
- All-cash transaction valued at $21.50 per share
- Integration of specialized cancer research pipeline into global portfolio
- Transition from independent public company to private subsidiary
Event Analysis
Day One Biopharmaceuticals, Inc. Material Event: Acquisition Summary
Day One Biopharmaceuticals has officially transitioned from an independent, public company to a wholly owned subsidiary of Servier Pharmaceuticals. This acquisition marks the end of Day One’s time as a standalone firm focused on cancer treatments for children and adults.
1. What happened?
Servier Pharmaceuticals acquired Day One through a merger. As of April 23, 2026, Day One is a subsidiary of Servier. Under the deal, each share of Day One stock (ticker: DAWN) converted into the right to receive $21.50 in cash, minus any applicable taxes.
2. When did it happen?
The deal closed on April 23, 2026. This followed a tender offer from Servier that ended at 11:59 p.m. Eastern Time on April 22, 2026. Servier accepted all shares that were properly submitted by that deadline.
3. Why did it happen?
The companies signed a merger agreement in early March 2026. Servier sought to integrate Day One’s specialized cancer research and drug pipeline into its global portfolio. Day One’s Board of Directors determined that this all-cash transaction provided the most immediate and certain value for its shareholders.
4. What this means for your investment
Day One is no longer a public company.
- The Stock: Trading of "DAWN" has ceased, and the stock has been delisted from the Nasdaq.
- The Cash: Shareholders are entitled to $21.50 per share. In most cases, this process is handled automatically by your brokerage firm, and you do not need to take manual action.
5. Who is affected?
- Investors: Your equity in Day One has been converted into a cash payment. You no longer hold a stake in the company.
- Employees/Leadership: The company is now under new management. The previous Board of Directors has stepped down, and Servier has appointed new leadership to oversee the subsidiary.
- Patients/Doctors: Servier now manages all of Day One’s clinical programs and is responsible for the future development of its cancer treatments.
6. What happens next?
Day One will no longer file financial reports with the SEC. It will continue its research and development work as a private subsidiary under Servier’s corporate umbrella.
7. Action items for former shareholders
- Check your account: Review your brokerage statement to confirm the $21.50 per share payment has been credited to your account.
- Physical certificates: If you held physical stock certificates rather than digital shares, you must follow the instructions provided by the paying agent to surrender your certificates and collect your payment.
- Update your portfolio: Because the company is now private, it is no longer tracked on public markets. Your investment in Day One is complete, and you should remove it from your active watchlists.
Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and should not be taken as professional investment advice. Always consult with a qualified financial advisor regarding your personal tax and investment situation.
Key Takeaways
- Trading of DAWN stock has ceased; shares are no longer public.
- Brokerages will automatically process the $21.50 per share cash payout.
- Shareholders holding physical certificates must contact the paying agent.
- The company will continue operations as a private subsidiary under Servier.
Why This Matters
This event marks the definitive end of Day One Biopharmaceuticals as an independent public entity, signaling a major consolidation in the oncology research sector. For investors, this is a critical 'exit' event that requires immediate attention to portfolio management and the verification of cash payouts.
Stockadora highlights this acquisition because it represents a total transition of control. Unlike standard earnings reports, this event permanently removes the ticker from the market, necessitating that shareholders take specific actions to finalize their investment journey and clear their watchlists.
Financial Impact
Shareholders receive $21.50 per share in cash; company delisted from public markets.
Affected Stakeholders
Learn More
About This Analysis
AI-powered summary derived from the original SEC filing.
Document Information
AI-Generated Analysis
This analysis is AI-generated from SEC filings. This is educational content, not financial advice. Always consult a financial advisor before making investment decisions.